Literature DB >> 20874727

Glioma IDH1 mutation patterns off the beaten track.

S Pusch, F Sahm, J Meyer, M Mittelbronn, C Hartmann, A von Deimling.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 20874727     DOI： 10.1111/j.1365-2990.2010.01127.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN： 0305-1846            Impact factor:   8.090


× No keyword cloud information.
  21 in total

1.  Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1.

Authors:  Tali Mazor; Charles Chesnelong; Aleksandr Pankov; Llewellyn E Jalbert; Chibo Hong; Josie Hayes; Ivan V Smirnov; Roxanne Marshall; Camila F Souza; Yaoqing Shen; Pavithra Viswanath; Houtan Noushmehr; Sabrina M Ronen; Steven J M Jones; Marco A Marra; J Gregory Cairncross; Arie Perry; Sarah J Nelson; Susan M Chang; Andrew W Bollen; Annette M Molinaro; Henrik Bengtsson; Adam B Olshen; Samuel Weiss; Joanna J Phillips; H Artee Luchman; Joseph F Costello
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-15       Impact factor: 11.205

Review 2.  Neuro-Oncology and Radiogenomics: Time to Integrate?

Authors:  A Lasocki; M A Rosenthal; S J Roberts-Thomson; A Neal; K J Drummond
Journal:  AJNR Am J Neuroradiol       Date:  2020-09-10       Impact factor: 3.825

3.  1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth.

Authors:  Catherine Gozé; Charlotte Bezzina; Eric Gozé; Valérie Rigau; Thierry Maudelonde; Luc Bauchet; Hugues Duffau
Journal:  J Neurooncol       Date:  2012-03-06       Impact factor: 4.130

4.  A novel fully automated MRI-based deep-learning method for classification of IDH mutation status in brain gliomas.

Authors:  Chandan Ganesh Bangalore Yogananda; Bhavya R Shah; Maryam Vejdani-Jahromi; Sahil S Nalawade; Gowtham K Murugesan; Frank F Yu; Marco C Pinho; Benjamin C Wagner; Bruce Mickey; Toral R Patel; Baowei Fei; Ananth J Madhuranthakam; Joseph A Maldjian
Journal:  Neuro Oncol       Date:  2020-03-05       Impact factor: 12.300

5.  Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.

Authors:  Giuseppe Lombardi; Giuseppe Corona; Luisa Bellu; Alessandro Della Puppa; Ardi Pambuku; Pasquale Fiduccia; Roberta Bertorelle; Marina Paola Gardiman; Domenico D'Avella; Giuseppe Toffoli; Vittorina Zagonel
Journal:  Oncologist       Date:  2015-04-10

6.  Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification.

Authors:  G Ening; F Osterheld; D Capper; K Schmieder; C Brenke
Journal:  J Cancer Res Clin Oncol       Date:  2015-01-11       Impact factor: 4.553

7.  Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.

Authors:  J A Carrillo; A Lai; P L Nghiemphu; H J Kim; H S Phillips; S Kharbanda; P Moftakhar; S Lalaezari; W Yong; B M Ellingson; T F Cloughesy; W B Pope
Journal:  AJNR Am J Neuroradiol       Date:  2012-02-09       Impact factor: 3.825

8.  Something old and something new about molecular diagnostics in gliomas.

Authors:  Craig Horbinski
Journal:  Surg Pathol Clin       Date:  2012-12-01

9.  Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.

Authors:  Shipra Agarwal; Mehar Chand Sharma; Prerana Jha; Pankaj Pathak; Vaishali Suri; Chitra Sarkar; Kunzang Chosdol; Ashish Suri; Shashank Sharad Kale; Ashok Kumar Mahapatra; Pankaj Jha
Journal:  Neuro Oncol       Date:  2013-03-13       Impact factor: 12.300

Review 10.  IDH mutations in human glioma.

Authors:  Won Kim; Linda M Liau
Journal:  Neurosurg Clin N Am       Date:  2012-05-31       Impact factor: 2.509
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.